SERIO - Side Effect Registry Immuno-Oncology
Focus of Research
The Side Effect Registry Immuno-Oncology (SERIO) documents rare, complex and severe side effects of immunotherapy since 2011. In cooperation with the Paul-Ehrlich Institute access to the data base is online since February 2020 (www.serio-registry.org) with more than 1700 cases from 27 national and international centers documented so far. We analyze the data bank with respect to clinical characteristics, risk factors, outcome and treatment of immune-related adverse events and regularly publish articles about specific topics of interest.
Via the registry we can also access biological samples especially of rare side effects like biopsies from patients with cardiomyositis or with neurological side effects to further investigate pathomechanisms.
Prof. Lucie Heinzerling, MD, MPH
Samuel Knauss, MD
Dirk Mentzer, MD
Natallia Treitinger, MD/study coordinator
Sarah Zierold, MD
» Abolhassani AR, Schuler G, Kirchberger MC, Heinzerling L. C-reactive protein as an early marker of immune-related adverse events. J Cancer Res Clin Oncol 2019;145(10):2625-31
» Heinzerling L, Ascierto PA, Dummer R, Gogas H, Grob JJ, Lebbe C, Long GV, McArthur G, Moslehi JJ, Neilan TG, Ribas A, Robert C, Schadendorf D, Wolchok JD, Hauschild A. Adverse events 2.0-Let us get SERIOs: New reporting for adverse event outcomes needed in the era of immunooncology. Eur J Cancer 2019;112:29-31
» Moreira A, Loquai C, Pföhler C, Kähler KC, Knauss S, Heppt MV, Gutzmer R, Dimitriou F, Meier F, Mitzel-Rink H, Schuler G, Terheyden P, Thoms KM, Türk M, Dummer R, Zimmer L, Schröder R, Heinzerling L. Myositis and neuromuscular side effects induced by immune checkpoint inhibitors. Eur J Cancer 2018;106:12-23
» Mahmood SS, Fradley MG, Cohen JV, Nohria A, Reynolds KL, Heinzerling L, Sullivan RJ, Damrongwatanasuk R, Chen CL, Gupta D, Kirchberger MC, Awadalla M, Hassan MZO, Moslehi JJ, Shah SP, Ganatra S, Thavendiranathan P, Lawrence DP, Groarke JD, Neilan TG. Myocarditis in Patients Treated With Immune Checkpoint Inhibitors. J Am Coll Cardiol 2018;71(16):1755-64
» Hofmann L, Forschner A, Loquai C, Goldinger SM, Zimmer L, Ugurel S, Schmidgen MI, Gutzmer R, Utikal JS, Göppner D, Hassel JC, Meier F, Tietze JK, Thomas I, Weishaupt C, Leverkus M, Wahl R, Dietrich U, Garbe C, Kirchberger MC, Eigentler T, Berking C, Gesierich A, Krackhardt AM, Schadendorf D, Schuler G, Dummer R, Heinzerling L. Cutaneous, gastrointestinal, hepatic, endocrine and renal side effects of anti-PD-1 therapy. Eur J Cancer 2016;60:190-209